Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zohydro
- Development stage
- Approved
- Lead developer
- Tabros
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Zohydro** is a Tabros topical fixed-dose cream containing clotrimazole 1% and hydrocortisone 1%. Clotrimazole is an imidazole antifungal that disrupts fungal ergosterol biosynthesis, while hydrocortisone is a low-potency glucocorticoid that reduces local inflammation, erythema, and pruritus. The product is marketed as a 10 g cream for fungal skin infections accompanied by inflammatory symptoms. ([multanpluspharmacy.com](https://multanpluspharmacy.com/products/zohydro-cream-10g))
- Brand names
- Zohydro
- Other names
- Zohydro Cream
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Zohydro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zohydro.